Tuberculosis remains one of the most consequential unfinished battles in global infectious disease control — and this sweeping 33-year analysis arrives at a moment when funding cuts threaten to reverse hard-won gains. For health-conscious adults and public health advocates alike, understanding the current TB landscape matters because MDR-TB and HIV-TB co-infection represent increasingly complex threats with direct implications for antibiotic resistance trajectories worldwide.
Drawing on the Global Burden of Disease Study 2023, researchers systematically quantified TB mortality, morbidity, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023. The analysis stratified outcomes by HIV status and drug-resistance profile using population attributable fraction modeling, and incorporated data streams ranging from vital registration and national surveillance to verbal autopsies and minimally invasive tissue sampling. Risk factor contributions — including alcohol use, smoking, and elevated fasting plasma glucose — were assessed through a comparative risk assessment framework, offering a nuanced decomposition of modifiable drivers. Progress toward the WHO End TB Strategy targets of a 95% mortality reduction and 90% incidence reduction by 2035 (relative to 2015 baselines) was explicitly evaluated.
This analysis is significant for several reasons beyond its scale. First, it arrives as global health financing contracts, creating an urgent baseline against which future setbacks can be measured. Second, the integration of MDR-TB stratification within the GBD framework is methodologically mature enough to illuminate regional divergence — certain high-burden nations may be approaching WHO targets while others remain deeply off-track. Third, the inclusion of metabolic and behavioral risk factors like hyperglycemia and alcohol positions TB firmly within the chronic disease ecosystem, not merely as an infectious disease problem. The primary limitation is the heterogeneity of underlying data quality across 204 territories; estimates in low-registry settings carry wider uncertainty intervals. As a large systematic meta-analysis from a top-tier infectious disease journal, this represents a definitive epidemiological benchmark — more confirmatory than paradigm-shifting, but essential infrastructure for evidence-based policy.